<DOC>
	<DOCNO>NCT03010683</DOCNO>
	<brief_summary>Arterial stiffness associate increase risk cardiovascular disease . Moreover , integrity endothelial glycocalyx play vital role vascular permeability , inflammation elasticity . Agonists Glucagon like peptide - 1 receptor ( GLP-1R ) use treatment type 2 diabetes mellitus ( T2DM ) . This category include exenatide liraglutide . These drug low glucose level inhibit secretion glucagon , promote release insulin response hyperglycemia , slow gastric emptying , augment satiety . Clinical study show GLP-1R agonist beneficial effect cardiovascular function diabetic patient healthy subject . The purpose study investigate patient T2DM without coronary artery disease ( CAD ) , patient T2DM CAD obese patient abnormal oral glucose tolerance test ( OGTT ) , change arterial stiffness , endothelial glycocalyx thickness coronary reserve flow ( CFR ) treatment metformin agonist GLP-1R .</brief_summary>
	<brief_title>Effects Agonists Glucagon Like Peptide - 1 Receptors ( GLP-1R ) Arterial Stiffness , Endothelial Glycocalyx Coronary Flow Reserve Patients With Coronary Artery Disease Patients With Diabetes Mellitus</brief_title>
	<detailed_description>The investigator study three group match age sex : 30 patient type 2 diabetes mellitus ( T2DM ) without coronary artery disease ( CAD ) , 30 patient T2DM CAD 30 obese patient ( BMI &gt; 30 Kg/m² ) abnormal oral glucose tolerance test ( OGTT ) . It randomize study metformin GLP-1R agonist treatment 1 year . All subject receive 1 year : ( ) GLP-1R agonist ( b ) metformin . At 0 , 3 , 6 12 month , 0 start point treatment , blood sample collect . At 0 , 3 , 6 12 month investigator measure : 1 . Carotid-femoral pulse wave velocity ( PWV , m/sec ) use tonometry Complior ( SP ALAM ) augmentation index ( AI , % ) method arteriography ( Arteriograph , TensioMed ) 2 . Perfused boundary region ( PBR , micrometer ) sublingual arterial microvessels ( range 5-25 micrometer ) use Sideview Darkfield imaging ( Microscan , Glycocheck ) . Increased PBR consider accurate non invasive index reduce endothelial glucocalyx thickness . 3 . Coronary flow reserve ( CFR ) leave anterior descend artery infusion adenosine use Doppler echocardiography . 4 . Determination follow parameter blood : glucose , insulin , free fatty acid , triglyceride , glycerol , C reactive protein ( CRP ) , transform growth factor-b ( TGF-b ) , Lipoprotein-Associated Phospholipase A2 ( LP-LPA2 ) , tumor necrosis factor-a ( TNF-a ) , interleukins 6 10 ( IL6 IL10 ) , propeptide type I procollagen ( PIP ) , propeptide procollagen type III ( PIIINP ) , matrix metallopeptidases 9 2 ( MMP ) , macrophage-colony stimulating factor ( MCSF ) , growth differentiation factor-15 ( GDF-15 ) , N-terminal pro b-type natriuretic peptide ( NT-proBNP ) galectin-3 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Patients type 2 diabetes mellitus ( T2DM ) without coronary artery disease ( CAD ) Patients T2DM CAD . Obese patient ( BMI &gt; 30 Kg/m² ) abnormal oral glucose tolerance test ( OGTT ) valvular heart disease congestive heart failure peripheral vascular disease liver kidney failure history alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Arterial stiffness</keyword>
	<keyword>Endothelial glycocalyx</keyword>
	<keyword>Coronary flow reserve</keyword>
</DOC>